Inaxaplin (VX-147) is a selective oral inhibitor targeting APOL1 channel function aimed at treating proteinuric kidney disease in FSGS patients with two APOL1 risk alleles. This evidence concerns the gene APOL1 and focal segmental glomerulosclerosis.